Stay updated on Inetetamab Plus Rapamycin for HER2+ Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the Inetetamab Plus Rapamycin for HER2+ Breast Cancer Clinical Trial page.

Latest updates to the Inetetamab Plus Rapamycin for HER2+ Breast Cancer Clinical Trial page
- Check4 days agoChange DetectedA new revision entry (v3.3.3) was added to the record history, and the HHS Vulnerability Disclosure link along with the previous revision entry (v3.3.2) were removed from the footer. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check11 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedRecord History now shows a new revision entry: v3.3.2, replacing the earlier v3.3.1. This is a metadata update to the page's version history and does not affect study data or other page content.SummaryDifference0.1%

- Check33 days agoChange DetectedAdded revision v3.3.1 and removed revision v3.2.0 from the record history.SummaryDifference0.1%

- Check41 days agoChange DetectedRemoved the lapse in government funding notice at the top of the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.9%

- Check55 days agoChange DetectedThe new screenshot shows an updated submission date in the Study Record Versions section for NCT04736589, while the rest of the page content remains the same. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check84 days agoChange DetectedAdded a government operating-status notice and updated version to v3.2.0; removed the previous v3.1.0 tag.SummaryDifference13%

Stay in the know with updates to Inetetamab Plus Rapamycin for HER2+ Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Inetetamab Plus Rapamycin for HER2+ Breast Cancer Clinical Trial page.